On January 3, 2022 Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, reported that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022 (Press release, Checkmate Pharmaceuticals, JAN 3, 2022, View Source [SID1234598107]). The pre-recorded webcast will be available on-demand starting on Monday, January 10 at 7:00am ET. Checkmate will also host 1×1 investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!